A major confirmation about the underscored role of the IGF-II-IRA axis in cancer has come from the failure of the IGF-IR blockers developed in the last few decades in phase-II clinical trials when used as monotherapy [47] suggesting that anti-cancer strategies blocking the IGF-II-IRA signal along with that generated by the IGFII-IGFIR axis cannot be disregarded in vivo. Here, IGF2 is linked to cancer.